1 billion anti-epileptic drugs re-opening Huahai left elacitan slow release film approved for listing

Medicines Network June 3, June 2, Huahai Pharmaceutical signed a notice, the company recently received the State Drug Administration approved the issuance of the left ethyl lasitan reprieve "drug registration approval", the drug is in accordance with the new 3 types of approval of production, as a result through a consistent evaluationAccording to Minet data, sales of left-braceitan tablets at the end of China's public medical institutions exceeded 1 billion yuan in 2019In February this year, Huahai Pharmaceutical's left ethyl lacitam tablets were approved with imitation of 4 categories of declarations, as if passing a consistent evaluationthe basic situation of drugdata show that the left ethyl lasitan reprieve is mainly used to treat epilepsy, developed by UCB INC, in September 2008 by the FDA approvedThe world's major manufacturers of the left Erazitan reprieve film are ACTAVIS LABS FL INC, APOTEX INC, TEVA PHARMS, etc., the domestic manufacturer is Shenzhen Xinlitai PharmaceuticalsIn recent years, China's public medical institutions terminal left eracetam tablet sales (unit: million yuan)In recent years, the number of end-of-life sales of left ethyl lasitan tablets in China's urban publichospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) has grown by more than 10%, exceeding the scale of 1 billion in 2019Huahai Pharmaceuticals said that the company's left ethyl Lasitan slow release film to obtain the "
drug registrationbatch", marking the domestic market to sell the drug qualifications, further enrich the company's product line, help to enhance the company's product market competitivenessAccording to the relevant national policies, the company's left ethyl lasitan slow release film according to the new 3 categories of approval production, as a consistent evaluation, and in the medical insurance payment to be appropriate support, medical institutions should give priority to
the procurement ofand in the clinical priority selection, is conducive to expanding the market sales of products, the company's operating performance has a positive impactUp to now, Huahai Pharmaceuticals has invested about 8.7 million yuan in research and development projects on the left-braceitan reprieve film